TeraRecon Launches AI-Driven Neuroimaging Platform

Article

TeraRecon Neuro reportedly offers six automated and customizable computed tomography (CT) perfusion maps that facilitate assessment of brain function in hemorrhagic and ischemic neurological cases.

A new artificial intelligence (AI)-powered neuroimaging platform may offer adjunctive benefits for timely assessment and treatment decisions in neurovascular emergencies.

One of the benefits of TeraRecon Neuro is automated screening for challenging cases involving possible intracerebral hemorrhages (ICHs) and large vessel occlusions (LVOs), according to TeraRecon, the manufacturer of the platform.

The company said TeraRecon Neuro enables radiologists to modify the platform’s algorithm to optimize AI outputs. TeraRecon noted the TeraRecon Neuro platform, viewable on diagnostic desktop viewers and via a mobile app, also enhances the assessment of brain function with six customizable computed tomography (CT) perfusion maps.

“We believe the best use case scenario is not autonomous AI, but rather expert clinical supervision that is augmented by AI-driven insights. TeraRecon Neuro was designed to accommodate all care team members and workflows, while simultaneously maintaining standardization across the care continuum to ensure timely delivery of coordinated care for numerous neurovascular emergencies,” noted Dan McSweeney, the president of TeraRecon.

Recent Videos
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Related Content
© 2025 MJH Life Sciences

All rights reserved.